Alzheimer's disease

Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Mon, 02/20/23 - 12:44 pm
Eisai
FDA
Alzheimer's disease
Leqembi
lecanemab
Biogen chairman to step down as new CEO walks thin line with Alzheimer's launch Leqembi
Fierce Pharma
Wed, 02/15/23 - 06:28 pm
Biogen
Chris Viehbacher
Stelios Papadopoulos
Pharma CEOs
Alzheimer's disease
Leqembi
FDA adds warning of 'larger areas of bleeding' in brain to Biogen's Aduhelm label
Endpoints
Tue, 02/14/23 - 11:01 am
Biogen
Aduhelm
FDA
Alzheimer's disease
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Mon, 02/6/23 - 06:21 pm
Eisai
Alzheimer's disease
drug launches
Leqembi
Prothena: Trial data underscores the potential of antibody in treating Alzheimer’s disease
Biopharma Reporter
Wed, 02/1/23 - 10:25 am
Protena
clinical trials
Alzheimer's disease
PRX005
Quince lays off 47% of staff, stakes sale sign for asset days after separate pipeline deal
Fierce Biotech
Tue, 01/31/23 - 10:29 am
Quince Therapeutics
layoffs
Alzheimer's disease
Cortexyme
Lighthouse Pharmaceuticals
HIV protease inhibitors
Early data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of study
Fierce Biotech
Thu, 01/26/23 - 05:12 pm
AC Immune
Alzheimer's disease
clinical trials
vaccines
ACI-24.060
Some Experts Say FDA Made the Right Call on Lilly's Donanemab
BioSpace
Tue, 01/24/23 - 10:31 am
Eli Lilly
FDA
Alzheimer's disease
donanemab
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
BioSpace
Tue, 01/24/23 - 10:25 am
Cassava Sciences
clinical trials
simufilam
Alzheimer's disease
Innovative Trial Design may have Cost Lilly’s Donanemab Accelerated Approval
BioSpace
Fri, 01/20/23 - 10:29 am
Eli Lilly
donanemab
FDA
clinical trials
Alzheimer's disease
clinical trial design
Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug
Yahoo/Reuters
Thu, 01/19/23 - 09:00 pm
Eli Lilly
FDA
donanemab
Alzheimer's disease
Neurology startup merges with Wilbur Ross-backed SPAC
BioPharma Dive
Thu, 01/19/23 - 08:57 pm
Aprinoia Therapeutics
Wilbur Ross
SPAC
Alzheimer's disease
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Thu, 01/19/23 - 10:15 am
Biogen
Eisai
Alzheimer's disease
Leqembi
lecanemab
New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s
Fierce Pharma
Fri, 01/13/23 - 10:59 am
Biogen
Chris Viehbacher
lecanemab
Alzheimer's disease
Pharma CEOs
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Wed, 01/11/23 - 11:04 pm
Eisai
Biogen
lecanemab
Europe
Alzheimer's disease
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
5 FDA decisions to watch in the first quarter
BioPharma Dive
Mon, 01/9/23 - 10:27 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Menareni
Elacestrant
breast cancer
Biomarin
Roctavian
hemophilia A
Acadia Pharmaceuticals
trofinetide
Rett Syndrome
Gilead Sciences
Trodelvy
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab

Pages